Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

ClinicalTrials.gov ID: NCT06786624

Public ClinicalTrials.gov record NCT06786624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Study identification

NCT ID: NCT06786624
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Neurocrine Biosciences; Industry
Enrollment: 200 participants

Conditions and interventions

Conditions

Major Depressive Disorder

Interventions

NBI-1065845 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 21, 2025
Primary completion: Jun 30, 2027
Completion: Jun 30, 2027
Last update posted: Oct 28, 2025

2025 – 2027

United States locations

U.S. sites: 18
U.S. states: 8
U.S. cities: 18

Facility	City	State	ZIP	Site status
Neurocrine Clinical Site	Little Rock	Arkansas	72204	Recruiting
Neurocrine Clinical Site	Garden Grove	California	92844	Completed
Neurocrine Clinical Site	Orange	California	92866	Recruiting
Neurocrine Clinical Site	Pico Rivera	California	90660	Recruiting
Neurocrine Clinical Site	San Diego	California	92103	Recruiting
Neurocrine Clinical Site	Upland	California	91786	Recruiting
Neurocrine Clinical Site	Hollywood	Florida	33024	Recruiting
Neurocrine Clinical Site	Maitland	Florida	32751	Recruiting
Neurocrine Clinical Site	Boston	Massachusetts	02116	Recruiting
Neurocrine Clinical Site	Watertown	Massachusetts	02472	Suspended
Neurocrine Clinical Site	Mount Kisco	New York	10549	Recruiting
Neurocrine Clinical Site	Avon Lake	Ohio	44012	Recruiting
Neurocrine Clinical Site	Westlake	Ohio	44145	Completed
Neurocrine Clinical Site	Dallas	Texas	75251	Recruiting
Neurocrine Clinical Site	Houston	Texas	77030	Recruiting
Neurocrine Clinical Site	Richmond	Texas	77407	Withdrawn
Neurocrine Clinical Site	The Woodlands	Texas	77381	Suspended
Neurocrine Clinical Site	Everett	Washington	98201	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06786624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 28, 2025 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06786624 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →